Skip to main content

Table 1 Clinical factors and HOXD10 methylation in 117 cases of HCC samples

From: Silencing HOXD10 by promoter region hypermethylation activates ERK signaling in hepatocellular carcinoma

Clinical factor No. HOXD10 methylation status *P value
Unmethylated n = 27 (23.1%) Methylated n = 90 (76.9%)
Age (year)     0.799
 < 60 80 19 61  
 ≥ 60 37 8 29  
Gender     0.248
 Male 101 21 80  
 Female 16 6 10  
HBV infection     0.762
 Yes 85 19 66  
 No 32 8 24  
Liver cirrhosis     0.093
 Yes 88 17 71  
 No 29 10 19  
Tumor size (cm)     0.231
 ≤ 5 37 6 31  
 > 5 80 21 59  
Number of lesions     0.681
 1 92 22 70  
 ≥ 1 25 5 20  
Differentiation     0.044*
 Well 8 4 4  
 Moderate 74 19 55  
 Poor 35 4 31  
TNM stage     0.377
 Stage I + stage II 52 14 38  
 Stage III + stage IV 65 13 52  
Lymph node metastasis     0.867
 Negative 112 26 86  
 Positive 5 1 4  
Vessel cancerous embolus     0.049*
 Negative 87 24 63  
 Positive 30 3 27  
  1. *P values are obtained from chi-square test, significant difference, *P < 0.05